← All trials
NCT04943068
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 10, 2021
- Primary completion
- Jun 30, 2022
- Completion date
- Dec 31, 2022
- First posted
- Jun 29, 2021
- Last posted
- Jun 29, 2021
- Enrollment
- 186
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Kwang Dong Pharmaceutical co., ltd.Lead sponsor
- Korea UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.